Education
About Us
Working with TipRanks
Follow Us
Daxor Corp (DE:DX5)
FRANKFURT:DX5
DX5 Stock Chart & Stats
€10.90
€0.30(4.11%)
At close: 4:00 PM EST
€10.90
€0.30(4.11%)
Day’s Range― - ―
52-Week Range€6.20 - €12.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
N/A
Enterprise Value€57.05M
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€112.00K
Price to Earnings (P/E)8.0
Beta0.40
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.62
Shares Outstanding5,827,225
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.60
Price to Sales (P/S)146.07
P/FCF Ratio-121.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.54Price Target Upside79.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€6.02M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a sizable equity cushion materially reduce refinancing and solvency risk, giving management durable financial flexibility to fund commercialization, R&D and working capital. This resilience supports multi-month scaling without urgent debt pressures or covenant constraints.
FDA 510(k) Clearance For Next-gen AnalyzerRegulatory clearance for a faster, portable blood volume analyzer is a structural product advantage: it broadens clinical use cases, eases site adoption, and supports reimbursement-driven outpatient deployments. This durable competitive edge can lift sustained revenue as placements scale.
Recent Capital RaiseA $9M registered direct offering materially strengthens liquidity to build inventory, fund production and expand the commercial team. That capital reduces near-term funding risk and supports execution of commercialization plans over the coming 2–6 months without immediate need for dilutive emergency financings.
Bears Say
Weak Cash GenerationRepeated negative operating and free cash flow indicate earnings have not reliably converted to cash, elevating execution risk. Sustained cash burn can force additional funding rounds or slow placements if revenue ramps lag, making near-term scaling contingent on continued external capital.
Volatile, Small Revenue BaseA small, volatile revenue stream and reliance on irregular spikes reduce predictability of margins and cash flow. This unstable top line undermines visibility for commercial scaling and makes multi-quarter performance improvements uncertain until recurring, repeatable revenue is established.
Operating Losses From ScalingOngoing R&D and commercial ramp investments caused operating losses in 2025, showing the commercialization phase is cash-consuming. If product placements or reimbursement uptake lag, continued investment could pressure margins and require further capital before the business achieves sustained operating profitability.
Daxor News
DX5 FAQ
What was Daxor Corp’s price range in the past 12 months?
Daxor Corp lowest stock price was €6.20 and its highest was €12.60 in the past 12 months.
What is Daxor Corp’s market cap?
Currently, no data Available
When is Daxor Corp’s upcoming earnings report date?
Daxor Corp’s upcoming earnings report date is Mar 04, 2027 which is in 358 days.
How were Daxor Corp’s earnings last quarter?
Daxor Corp released its earnings results on Feb 26, 2026. The company reported €1.621 earnings per share for the quarter, beating the consensus estimate of N/A by €1.621.
Is Daxor Corp overvalued?
According to Wall Street analysts Daxor Corp’s price is currently Undervalued.
Does Daxor Corp pay dividends?
Daxor Corp does not currently pay dividends.
What is Daxor Corp’s EPS estimate?
Daxor Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daxor Corp have?
Daxor Corp has 5,827,225 shares outstanding.
What happened to Daxor Corp’s price movement after its last earnings report?
Daxor Corp reported an EPS of €1.621 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.885%.
Which hedge fund is a major shareholder of Daxor Corp?
Currently, no hedge funds are holding shares in DE:DX5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daxor Corp
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
DX5 Stock 12 Month Forecast
Average Price Target
€19.54
▲(79.30% Upside)
Technical Analysis
Options Prices
Currently, No data available
---